Opendata, web and dolomites


Unravelling the Interplay between Metabolism, Gut Microbiome and Adaptive Immunity in Amyotrophic Lateral Sclerosis

Total Cost €


EC-Contrib. €






 MegaALS project word cloud

Explore the words cloud of the MegaALS project. It provides you a very rough idea of what is the project "MegaALS" about.

warranted    innovative    epidemiological    rare    substantially    physiology    tested    multiple    translate    profiling    adaptive    contrast    therapeutic    interplay    animal    intervention    immunity    spouses    microbiome    quality    mouse    treatments    treatment    sod1g93a    metagenomic    platforms    microbiota    donors    uses    population    healthy    etiopathogenesis    caloric    possibility    preventive    lifestyle    overarching    transplant    leads    molecular    central    individuals    lateral    explore    usefulness    environmental    metabolism    als    unrelated    combines    controls    model    immune    nervous    stockholm    effectiveness    prevention    physiological    first    diagnosis    systemic    ultimate    observational    compare    amyotrophic    combining    offers    death    proteomic    lack    experimental    hypothesize    neurodegenerative    siblings    underlying    devastating    fecal    regimen    disease    gut    understand    interactions    profiles    contributes    human    strategy    risk    significantly    sclerosis    disorder    specificity    mechanisms    few    diet   

Project "MegaALS" data sheet

The following table provides information about the project.


Organization address
address: Nobels Vag 5
postcode: 17177

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 1˙499˙196 €
 EC max contribution 1˙499˙196 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-STG
 Funding Scheme ERC-STG
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2023-10-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 1˙499˙196.00


 Project objective

Amyotrophic lateral sclerosis (ALS) is a rare but devastating neurodegenerative disorder that in lack of effective treatments leads to death within a few years of diagnosis. ALS is increasingly being recognized as a systemic disease affecting not only the central nervous system but also other physiological aspects. We hypothesize that there is a disease-specific interplay between metabolism, gut microbiome and adaptive immunity, which substantially contributes to the etiopathogenesis of ALS. The overarching aim of this project is therefore to explore such interplay, and to assess the effectiveness of a treatment regimen that specifically targets it. Using a population-based case-control study of ALS in Stockholm, I will first characterize the complex interactions between metabolism, microbiome, and immunity in ALS, through comprehensive proteomic, metagenomic and immune-response profiling. The specificity of these interactions will be tested in contrast to healthy individuals at high risk for ALS (siblings), individuals with similar environmental and lifestyle factors (spouses), and unrelated population-controls. I will then use an established ALS mouse model (SOD1G93A) to understand the usefulness of combining a high-caloric diet with a fecal microbiota transplant from healthy human donors in disease prevention and treatment. To better understand the underlying mechanisms, I will compare microbiome and immune-response profiles before and after the intervention. The proposed research is unique as it 1) combines innovative molecular platforms with a high-quality epidemiological study design, 2) uses a novel strategy of investigating multiple aspects of human physiology, and 3) offers a possibility to directly translate findings between human observational and animal experimental studies. The ultimate goal is to significantly advance our knowledge about ALS as a disease, and more importantly to identify novel and highly warranted preventive and therapeutic targets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEGAALS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEGAALS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

SECReTE (2018)

Enhancing biological drug production through protein secretion

Read More  

EVOMENS (2020)

The evolution of menstruation in primates

Read More  

RTMFRM (2019)

Room Temperature Magnetic Resonance Force Microscopy

Read More